- Home
- VINP vs ABUS Comparison
VINP vs ABUS Comparison
Compare VINP & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VINP
- ABUS
- Stock Information
- Founded
- VINP 2009
- ABUS 2005
- Country
- VINP Brazil
- ABUS United States
- Employees
- VINP N/A
- ABUS N/A
- Industry
- VINP Investment Managers
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- VINP Finance
- ABUS Health Care
- Exchange
- VINP Nasdaq
- ABUS Nasdaq
- Market Cap
- VINP 593.2M
- ABUS 685.7M
- IPO Year
- VINP 2021
- ABUS N/A
- Fundamental
- Price
- VINP $9.57
- ABUS $3.20
- Analyst Decision
- VINP Strong Buy
- ABUS Strong Buy
- Analyst Count
- VINP 2
- ABUS 4
- Target Price
- VINP $13.25
- ABUS $5.50
- AVG Volume (30 Days)
- VINP 49.1K
- ABUS 677.7K
- Earning Date
- VINP 08-06-2025
- ABUS 07-31-2025
- Dividend Yield
- VINP 6.79%
- ABUS N/A
- EPS Growth
- VINP N/A
- ABUS N/A
- EPS
- VINP 0.38
- ABUS N/A
- Revenue
- VINP $126,696,258.00
- ABUS $6,403,000.00
- Revenue This Year
- VINP $70.28
- ABUS $3.35
- Revenue Next Year
- VINP $14.37
- ABUS N/A
- P/E Ratio
- VINP $25.14
- ABUS N/A
- Revenue Growth
- VINP 57.51
- ABUS N/A
- 52 Week Low
- VINP $8.66
- ABUS $2.71
- 52 Week High
- VINP $11.62
- ABUS $4.73
- Technical
- Relative Strength Index (RSI)
- VINP 47.61
- ABUS 37.60
- Support Level
- VINP $9.41
- ABUS $3.29
- Resistance Level
- VINP $9.70
- ABUS $3.65
- Average True Range (ATR)
- VINP 0.23
- ABUS 0.13
- MACD
- VINP 0.01
- ABUS -0.03
- Stochastic Oscillator
- VINP 43.48
- ABUS 14.29
About VINP Vinci Partners Investments Ltd.
Vinci Partners Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Equity, Equities, Real Assets, Credit, Global IP&S, and Corporate Advisory. The company's majority of its revenue comes from the Private Equity segment, which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.